SRX news

CERO Therapeutics entered into a definitive stock purchase agreement to sell its subsidiary CERO Therapeutics, Inc. to SRX Global for shares of SRX common stock and the forgiveness of a secured promissory note.

SRX Global has executed a definitive agreement to purchase all shares of CERo Therapeutics Holdings, Inc., aiming to integrate its biotechnology operations. This M&A transaction provides intended working capital relief to the seller.

SRX Global has secured an amendment and consent to a stock repurchase plan allowing the repurchase of up to 10 million common shares or 50% of outstanding stock under a $20 million cap.

SRX Global issued a consolidated senior secured promissory note consolidating previous advances up to $11,666,108.77 with an option for additional loans.

The company submitted a regulatory update, typically containing material information such as financial results or operational updates.